As a proof of concept study for further clinical development of this strategy, we here establish synthetic cblb siRNA treatment of polyclonal CD8+ T cells prior to ACT as a therapeutic approach to elicit enhanced DC-based tumor vaccine efficacy. The gene discussed is CD8A; the disease is neoplasm.